Risk of progression of Barrett's esophagus in patients with cirrhosis

Table 3 Incidence rates of dysplasia and esophageal adenocarcinoma in cases vs controls

	Non-cirrhotic controls	Cirrhotic cases	P value
	(95%CI)	(95%CI)
No dysplasia at baseline
Person-years	866.4	176.1	-
LGD incidence per 100-person year	2.8 (1.9, 4.1)	4.0 (1.9, 8.4)	0.40
HGD incidence per 100-person year	0.92 (0.46, 1.8)	0.57 (0.08, 4.0)	0.65
EAC incidence per 100-person year	0.46 (0.17, 1.2)	0.57 (0.08, 4.0)	0.85
HGD/EAC incidence per 100-person year	1.4 (0.79, 2.4)	1.1 (0.28, 4.6)	0.80
LGD at baseline
Person-years	86.9	14.6	-
HGD incidence per 100-person year	5.8 (2.4, 13.8)	6.9 (0.97, 48.8)	0.87
EAC incidence per 100-person year	2.3 (0.58, 9.2)	6.9 (0.97, 48.8)	0.37
HGD/Cancer incidence per 100-person year	8.1 (3.8, 16.9)	13.7 (3.4, 55.0)	0.51

LGD: Low grade dysplasia; HGD: High grade dysplasia; EAC: Esophageal Adenocarcinoma.